Heartbreaking Cardiac Amyloidosis: How Light Chain Amloidosis Changed My Life


, ,

By Marty Vanderlaan

Photo by: Dennis Schrader Photography | http://dennisschraderphoto.com

I spent my career developing monoclonal antibody (Mab) therapeutics. One of our standard tests was to quantify noncovalently linked light chains that can be dissociated from the antibodies, the result of failure to form critical S-S bonds linking the light chain to the heavy chain.  Continue reading

The Changing Role of the Clinical Pharmacologist in the Advancing Landscape of Cancer Therapy


, , , , ,

By: Konstantine W. Skordos

Preclinical akon-skordos_photond early clinical development in oncology are among the most challenging of any therapy area. Once potential compounds demonstrate a measure of promise with in vitro and in vivo disease models, a race begins to deliver it to patients in desperate need of new therapies. Rarely are compound properties fully explored in early trials involving healthy volunteers, historically due to safety considerations for cytotoxic agents potentially active in malignant neoplastic disease. Even in the setting of favorable safety profiles for some molecularly targeted agents, it will rarely be ethical to delay entry into patients who may benefit from the potential medicine. Continue reading

Designing Polymers for Amorphous Solid Dispersions


, , , ,

By: Laura I. Mosquera-Giraldo and Lynne S. Taylor

laura-mosquera-giraldo_photolynne-taylor_photoImagine spending billions of dollars in the discovery of a new drug, and then realizing that it is impractical to administer it orally because it cannot reach the systemic circulation and achieve a therapeutic effect. This is the case for many emerging drugs that are insoluble in water, and it poses a challenge, because drugs must be firstly dissolved in order to be absorbed and reach their site of action. Continue reading

Back to the Basics: The Importance of Rational Nanoparticle Design for Cancer Treatment


, , ,

By Jason Bugno

bugno_photoPolymeric nanoparticles (NPs) have been heavily investigated as potential drug delivery tools for a few decades now, yet only a few have found their way into clinical trials. In light of this, many researchers have taken a step back to reevaluate their progress and look at what really matters when designing NPs for drug delivery. For instance, recently published works, such as this review by Wilhelm et al., have highlighted the importance of understanding the fundamental mechanisms governing how NPs interact with biological systems. Continue reading